Agreed. I’ve always said stock manipulation exis
Post# of 72440
Another major factor is the nature of drug development. If you look at the complete chart of successful companies like PCYC, REGN and JAZZ, one thing they have in common is a very long down period followed by a sharp rise near the end. Clinical trials, data analysis, FDA interactions and partnership negotiations take a very long time. During this period companies have to dilute to survive so SP will decline. No doubt shorts forced Leo to dilute a lot more at much lower prices.
Were those companies all attacked by shorts during the down period? I don’t know. But I do know some were traded on Nasdaq at the time, so OTC MMs couldn’t be blamed as a factor. Anyway, just want to point out what IPIX is going through is just part of life as a pre-revenue biotech.